Dowling & Yahnke LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 200,911 shares of the biopharmaceutical company’s stock after purchasing an additional 3,236 shares during the period. Dowling & Yahnke LLC’s holdings in Pfizer were worth $9,288,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Home Federal Bank of Tennessee increased its holdings in shares of Pfizer by 0.8% during the 4th quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock worth $1,297,000 after buying an additional 249 shares during the last quarter. Advocacy Wealth Management Services LLC increased its holdings in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 258 shares during the last quarter. Viridian Ria LLC increased its holdings in shares of Pfizer by 0.9% during the 4th quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 280 shares during the last quarter. Trust Co. of Oklahoma increased its holdings in shares of Pfizer by 4.4% during the 4th quarter. Trust Co. of Oklahoma now owns 7,079 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 300 shares during the last quarter. Finally, Capital City Trust Co. FL increased its holdings in shares of Pfizer by 6.9% during the 4th quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 330 shares during the last quarter. Hedge funds and other institutional investors own 69.49% of the company’s stock.

NYSE:PFE opened at $39.38 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.57 and a quick ratio of 1.33. The company has a market cap of $234.42 billion, a P/E ratio of 13.13, a P/E/G ratio of 2.37 and a beta of 0.75. Pfizer Inc. has a fifty-two week low of $34.37 and a fifty-two week high of $46.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the company posted $0.62 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.86 EPS for the current year.

In other Pfizer news, EVP Douglas M. Lankler sold 38,800 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total value of $1,598,172.00. Following the completion of the transaction, the executive vice president now owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mikael Dolsten sold 149,553 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the completion of the transaction, the insider now directly owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. Insiders have sold a total of 332,526 shares of company stock valued at $14,346,539 in the last ninety days. 0.09% of the stock is currently owned by corporate insiders.

A number of analysts have recently issued reports on PFE shares. ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Citigroup restated a “neutral” rating and set a $41.00 price target on shares of Pfizer in a report on Wednesday, February 20th. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price target on shares of Pfizer in a report on Tuesday, February 19th. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, March 28th. Finally, Credit Suisse Group set a $45.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, December 26th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.61.

TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Shares Bought by Dowling & Yahnke LLC” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/pfizer-inc-pfe-shares-bought-by-dowling-yahnke-llc/2980474.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Understanding Specialty Certificates of Deposit

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.